IDEXX Laboratories, Inc. (NASDAQ:IDXX) has been given an average recommendation of “Buy” by the eight ratings firms that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, five have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $206.67.
IDXX has been the topic of several recent analyst reports. Aegis reissued a “sell” rating on shares of IDEXX Laboratories in a report on Friday, December 8th. BidaskClub downgraded IDEXX Laboratories from a “hold” rating to a “sell” rating in a report on Saturday, December 16th. Piper Jaffray Companies initiated coverage on IDEXX Laboratories in a report on Tuesday, January 16th. They issued an “overweight” rating and a $200.00 target price on the stock. Canaccord Genuity reissued a “buy” rating and issued a $210.00 target price on shares of IDEXX Laboratories in a report on Monday, January 29th. Finally, Zacks Investment Research downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, January 31st.
In other IDEXX Laboratories news, CEO Jonathan W. Ayers sold 18,000 shares of the company’s stock in a transaction on Tuesday, January 9th. The stock was sold at an average price of $165.15, for a total transaction of $2,972,700.00. Following the transaction, the chief executive officer now owns 1,077,112 shares of the company’s stock, valued at approximately $177,885,046.80. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, VP Brian P. Mckeon sold 6,602 shares of the company’s stock in a transaction on Monday, February 5th. The stock was sold at an average price of $181.36, for a total value of $1,197,338.72. Following the transaction, the vice president now directly owns 47,040 shares in the company, valued at approximately $8,531,174.40. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 91,736 shares of company stock worth $16,193,502. Company insiders own 2.77% of the company’s stock.
Shares of IDEXX Laboratories (NASDAQ:IDXX) traded up $1.57 on Wednesday, hitting $204.74. The stock had a trading volume of 403,815 shares, compared to its average volume of 594,463. The firm has a market cap of $17,780.00, a P/E ratio of 62.21, a P/E/G ratio of 2.50 and a beta of 0.58. The company has a quick ratio of 0.80, a current ratio of 0.97 and a debt-to-equity ratio of -11.26. IDEXX Laboratories has a fifty-two week low of $146.09 and a fifty-two week high of $205.90.
IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Thursday, February 1st. The company reported $0.77 EPS for the quarter, topping the consensus estimate of $0.73 by $0.04. The business had revenue of $506.00 million for the quarter, compared to the consensus estimate of $490.51 million. IDEXX Laboratories had a negative return on equity of 432.19% and a net margin of 13.36%. IDEXX Laboratories’s revenue was up 14.2% compared to the same quarter last year. During the same period in the previous year, the business earned $0.58 EPS. sell-side analysts anticipate that IDEXX Laboratories will post 4.09 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “IDEXX Laboratories, Inc. (IDXX) Given Consensus Recommendation of “Buy” by Brokerages” was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this story on another site, it was illegally copied and republished in violation of international copyright law. The correct version of this story can be accessed at https://sportsperspectives.com/2018/03/12/idexx-laboratories-inc-idxx-given-consensus-recommendation-of-buy-by-brokerages.html.
IDEXX Laboratories Company Profile
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.